Luminescence Assays

In this application note three ATP monitoring luminescence assays were assessed and compared head-to-head: (i) ATPlite™ from Revvity, (ii) ATPlite™ 1step from Revvity and (iii) ATP assay kit from a competitor company.

AlphaLISA and LANCE (TR-FRET) biomarker assays can be used to measure ECM-associated protein modulation caused by human transforming growth factor-beta (TGF-β) induction of EMT in a 3D Spheroid model of human prostate carcinoma.

Discover the cutting-edge of luminescence assay technology, offering unparalleled sensitivity and dynamic range for applications in gene expression, cell viability, and drug development. Experience high-throughput, cost-effective detection with minimal interference and simple automation. Check out our brochure to learn more about how this innovative technology can enhance your research studies. For research use only. Not for use in diagnostic procedures.

In this application note, we demonstrate an efficient cell-based workflow for the assessment of EGF treatment effects in a cellular model of human skin cancer. Treatment effects on several intracellular signaling pathways were examined using Revvity’s homogeneous, no-wash AlphaLISA ™ SureFire® Ultra assays. To determine concurrent time-dependent effects of different EGF concentrations on cellular health and proliferation, ATP concentrations were assessed with ATPlite ® 1step luminescence assay and cultures were fluorescently labeled, imaged and analyzed using the Operetta CLS™ high-content analysis system.

3D cell cultures offer a more physiologically relevant option, but there are currently only a few high throughput screening (HTS) 3D systems that have high consistency and easily allow integration with downstream analysis methods. In this application note, we demonstrate the creation of an advanced 3D primary human hepatocyte (PHH) model using the RASTRUM platform that seamlessly integrates with Revvity’s HTS technologies.

In the process of developing new therapeutic molecules, toxicity – whether it is to be avoided or whether it is desired – is an important feature to consider as early as possible in the development flow.

Breast cancer tumors can adapt to immune cell infiltration by responding to the increased concentration of interferon gamma (IFN-ɣ) and other cytokines secreted by subsets of T lymphocytes with the upregulation of the immune checkpoint proteins such as Programmed cell death ligand 1 (PD-L1). These checkpoint proteins allow the tumors to evade immune targeting and reduce the immune response, thus promoting tumor progression. In this application note, you will learn: How exogenous addition of IFN-ɣ effects the expression of PD-L1 and secretion of several cytokines in cultures of HCC38 cells (a triple-negative breast cancer cell line) How co-culturing activated immune cells and breast cancer cells stimulates differential expression of some immune checkpoint and inflammatory biomarkers compared to culturing cells alone with PBMC-conditioned media. How to rapidly measure multiple biomarkers in cell culture supernatant and lysates from the same wells of a culture dish to examine protein expression profiles from cancer and immune cell culture models using AlphaLISA assays together with ATPlite 1step and the EnVision multimode plate reader.

Luciferase assays are essential for examining transcriptional gene expression, virus life cycles, and cell viability. These assays play a crucial role in drug development, particularly in reporter gene, cytotoxicity, and cell proliferation studies. Our luminescence assays encompass both reporter gene and ATP-monitoring applications. Check out our flyer to learn about our luciferase luminescence assay options that allow high sensitivity in a convenient microplate format.

This application note demonstrates how compound’s mechanism of action and potential cytotoxic effects can be deciphered thanks to the combination of AlphaLISA ™ , HTRF ™ or AlphaLISA ™ SureFire ® Ultra ™ immunoassays with ATPlite™ 1step cell viability assay.

Chimeric antigen receptor (CAR) T-cell therapy has transformed the field of immuno-oncology providing a novel approach to treating certain blood cancers. As innovation progresses with the design of next-generation chimeric receptors and a better understanding of the tumor microenvironment, CAR-T therapy has the potential to also revolutionize therapies for treating solid tumors. Whether you are looking to characterize scFv binding capabilities of your chimeric receptor, assess vector transduction efficiency of your CAR construct, measure T-cell proliferation and toxicity, or assess effector cell function of your CAR-T therapy, we have the solutions to fit your needs. Learn more in this flyer about the products designed to support your CAR-T research!

This application note explores how HTRF based immunoassays enhance BRD4-targeted degradation studies, providing insights into leukemia research and accelerating drug discovery.